HAIFA, Israel--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that Griffin Securities has initiated independent research coverage of Pluristem’s stock. The research report can be found on http://www.griffinsecurities.com/, the content of which is not part of this press release.
